FBN2 and metastatic neoplasm: The median survival time in the group with low cCA 15-3 (< 127 IU/l) was 26.9 months compared with 27.7 months in the group with high cCA 15-3 levels (> 127 IU/l). The median time for the development of metastatic disease in the mBC cohort was 25.6 months (range 0–291.6 months) and the median follow-up time was 26.4 months.